Thieda P et al. An economic review of compliance with medication therapy in the treatment of schizophrenia.

Psychiatr Serv. 2003;54(4):508–516. doi:10.1176/appi.ps.54.4.508.

Kennedy JL et al. The social and economic burden of treatment-resistant schizophrenia: a systematic literature

review. Int Clin Psychopharmacol. 2014;29(2):63–76. doi:10.1097/YIC.0b013e32836508e6.

Davies L, Drummond M. The economic burden of schizophrenia. Psychiatr Bull. 1990;14:522–525.

Keshavan MS et al. Schizophrenia, “just the facts”: what we know in 2008. Part 3: neurobiology. Schizophr Res.

2008;106(2/3):89–107. doi:10.1016/j.schres.2008.07.020.

Bakhshi K, Chance SA. The neuropathology of schizophrenia: a selective review of past studies and emerging

themes in brain structure and cytoarchitecture. Neuroscience. 2015;303:82–102.

doi:10.1016/j.neuroscience.2015.06.028.

Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III—The final common pathway.

Schizophr Bull. 2009;35(3):549–562. doi:10.1093/schbul/sbp006.

Schwartz TL et al. Glutamate neurocircuitry: theoretical underpinnings in: schizophrenia. Front Pharmacol.

2012;3:1–11. doi:10.3389/fphar.2012.00195.

Lodge DJ, Grace AA. Developmental pathology, dopamine, stress and schizophrenia. Int J Dev Neurosci.

2011;29(3):207–213. doi:10.1016/j.ijdevneu.2010.08.002.

Seeman P. Reviews and overviews does fast dissociation from the dopamine D 2 receptor explain the action of

atypical antipsychotics ? A new hypothesis. Am J Psychiatry. 2001;158(March):360–369.

doi:10.1176/appi.ajp.158.3.360.

Kapur S et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind

PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514–520.

doi:10.1176/appi.ajp.157.4.514.

Anticevic A et al. Connectivity, pharmacology, and computation: toward a mechanistic understanding of neural

system dysfunction in schizophrenia. Front Psychiatry. 2013;4:1–21. doi:10.3389/fpsyt.2013.00169.

Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophr Bull. 2012;38(5):920–926.

doi:10.1093/schbul/sbs076.

Howes O et al. Glutamate and dopamine in schizophrenia : an update for the 21 st century. J Psychopharmacol.

2015;29(2):97–115.

Gruber O et al. Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate

system. Front Psychiatry. 2014;5:1–11. doi:10.3389/fpsyt.2014.00032.

Garey LJ et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol

Neurosurg Psychiatry. 1998;65(4):446–453. doi:10.1136/jnnp.65.4.446.

Nasrallah H et al. Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and

treatment. Epidemiol Psychiatr Sci. 2011;20(04):317–327. doi:10.1017/S204579601100062X.

Fitzsimmons J et al. Review of functional and anatomical brain connectivity findings in schizophrenia. Curr Opin

Psychiatry. 2013;26(2):172–187. doi:10.1097/YCO.0b013e32835d9e6a.

Moskowitz A, Heim G. Eugen Bleuler’s Dementia Praecox or the Group of Schizophrenias (1911): a centenary

appreciation and reconsideration. Schizophr Bull. 2011;37(3):471–479. doi:10.1093/schbul/sbr016.

Tandon R et al. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res.

2009;110(1–3):1–23. doi:10.1016/j.schres.2009.03.005.

Zipursky RB et al. The myth of schizophrenia as a progressive brain disease. Schizophr Bull. 2013;39(6):1363–

1372. doi:10.1093/schbul/sbs135.

Hegarty JD et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J

Psychiatry. 1994;151(10):1409–1416.

Abi-Dargham A et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl

Acad Sci USA. 2000;97(14):8104–8109. doi:10.1073/pnas.97.14.8104.

American Psychiatric Association. Schizophrenia spectrum and other psychotic disorders. In: American

Psychiatric Publishing, ed. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA:

American Psychiatric Publishing; 2013:87–122.

Dufresne RL. Issues in polypharmacotherapy: focus on depression in schizophrenia. Psychopharmacol Bull.

1995;31(4):789–796.

Palmer BA, Pankratz VS, Bostwick JM. The Lifetime Risk of Suicide in Schizophrenia. 2005;62:247–253.

doi:10.1001/archpsyc.62.3.247.Text.

American Psychiatric Association. Personality disorders. In: American Psychiatric Publishing, ed. Diagnostic and

Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013:645–684.

Elis O et al. Psychosocial treatments for negative symptoms in schizophrenia: current practices and future

directions. Clin Psychol Rev. 2013;33(8):914–928. doi:10.1016/j.cpr.2013.07.001.

Keshavan MS et al. Schizophrenia, “Just the Facts” 6. Moving ahead with the schizophrenia concept: from the

elephant to the mouse. Schizophr Res. 2011;127(1–3):3–13. doi:10.1016/j.schres.2011.01.011.

Lako IM et al. The course of depressive symptoms and prescribing patterns of antidepressants in schizophrenia in

a one-year follow-up study. Eur Psychiatry. 2012;27(4):240–244. doi:10.1016/j.eurpsy.2010.10.007.

Dufresne RL et al. Bupropion and thiothixene versus placebo and thiothixene in the treatment of depression in

schizophrenia. Drug Dev Res. 1988;12(3/4):259–266.

Becker RE. Depression in Schizophrenia. Psychiatr Serv. 1988;39(12):1269–1275. doi:10.1176/ps.39.12.1269.

Mandel MR et al. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics.

Arch Gen Psychiatry. 1982;39(2):197–203. doi:10.1001/archpsyc.1982.04290020051010.

Häfner H et al. Depression, negative symptoms, social stagnation and social decline in the early course of

schizophrenia. Acta Psychiatr Scand. 1999;100(2):105–118. doi:10.1111/j.1600-0447.1999.tb10831.x.

Insel TR. Rethinking schizophrenia. Nature. 2010;468(7321):187–193. doi:10.1038/nature09552.

Davidson L, McGlashan TH. The varied outcomes of schizophrenia. Can J Psychiatry. 1997;42(1):34–43.

Lieberman JA et al. Factors influencing treatment response and outcome of first-episode schizophrenia:

implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57(9:):5–9.

Schennach R et al. Treatment Response in First-episode Schizophrenia. Clin Psychopharmacol Neurosci.

2012;10(2):78–87.

Jobe TH, Harrow M. Long-term outcome of patients with schizophrenia: a review. Can J Psychiatry.

2005;50(14):892–900.

Dixon LB et al. The 2009 Schizophrenia PORT psychosocial treatment recommendations and summary

statements. Schizophr Bull. 2009;36(1):48–70. doi:10.1093/schbul/sbp115.

Perkins DO et al. Relationship between duration of untreated psychosis and outcome in first-episode

schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162(10):1785–1804.

Lehman AF et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J

Psychiatry. 2004;161(2, Suppl):1–56. doi:10.1176/appi.books.9780890423363.45859.

Leucht S et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review

and meta-analysis. Lancet. 2012;379(9831):2063–2071. doi:10.1016/S0140-6736(12)60239-6.

Trzepacz PT et al. The Psychiatric Mental Status Examination. Oxford University Press; 1993.

Leucht S et al. What does the PANSS mean? Schizophr Res. 2005;79(2/3):231–238.

OverallJE, Gorham DR. The brief psychiatric rating scale. Psychol Reports vol. 1962;10:799–812.

Dean CE et al. Clinical rating scales and instruments: how do they compare in assessing abnormal, involuntary

movements? J Clin Psychopharmacol. 2004;24(3):298–304.

Guy W. Manual for Psychopharmacology: Revised. Rockville,MD: US Department of Health, Education and

WelfarePublic Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH

Psychopharmacology Research Branch, Division of Extramural Research Program; 1976.

López-Muñoz F et al. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry.

2005;17(3):113–135. doi:10.1080/10401230591002002.

Gardos G, Cole JO. Weight reduction in schizophrenics by molindone. Am J Psychiatry. 1977;134(3):302–304.

Dufresne RL et al. Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacol Bull.

1993;29(2):249–255.

Popovic D et al. Revisiting loxapine: a systematic review. Ann Gen Psychiatry. 2015;14(1):10–17.

doi:10.1186/s12991-015-0053-3.

Kane J et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Arch Gen Psychiatry. 1988;45(9):789–796.

Alvir JM et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N EnglJ Med.

1993;329(3):162–167. doi:10.1056/NEJM199307153290303.

Jalenques I. Drug-resistant schizophrenia treatment options. CNS Drugs. 1996;5(1):8–23.

Hyde N et al. Prevalence of cardiovascular and metabolic events in patients prescribed clozapine: a retrospective

observational, clinical cohort study. Curr Drug Saf. 2015;10:125–131.

Ronaldson KJ et al. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75

cases and 94 controls. Aust N Z J Psychiatry. 2011;45(6):458–465. doi:10.1016/j.hlc.2010.06.772.

Hatton J et al. Clozapine-induced myocarditis. Tex Hear Inst J. 2015;42(2):155–157.

Meltzer H. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2012;64(1):120928131129008.

doi:10.1146/annurev-med-050911-161504.

Fenton M et al. Thioridazine for schizophrenia (review). Cochrane Database Syst Rev. 2011;(5):1–149.

doi:10.1002/14651858.CD001944.pub2.

Lieberman JA et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med.

2005;353(12):1209–1223. doi:10.1056/NEJMoa1404304.

Allison DB et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry.

1999;156(11):1686–1696.

Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm.

1996;53(17):2079–2081.

Osser DN et al. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry. 1999;60(11):767–

770. doi:10.4088/JCP.v60n1109.

Gaulin BD et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry. 1999;156(8):1270–1272.

Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001;21(4):369–374.

doi:10.1097/00004714-200108000-00003.

Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and

olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63(5):425–433.

doi:10.4088/JCP.v63n0509.

Lambert BL et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in Veterans Health

Administration patients with schizophrenia. Am J Epidemiol. 2006;164(7):672–681. doi:10.1093/aje/kwj289.

Kane J et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled

trial. Schizophr Res. 2007;90(1–3):147–161. doi:10.1016/j.schres.2006.09.012.

Lieberman JA. Comparative effectiveness of antipsychotic drugs. Arch Gen Psychiatry. 2006;63(3):1069–1072.

doi:10.1176/appi.ajp.160.3.590-a.

Carrillo JA et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steadystate concentration of olanzapine. J Clin Psychopharmacol. 2003;23(2):119–127.

Friedman JH. Atypical antipsychotic drugs in the treatment of Parkinson’s disease. J Pharm Pract.

2011;24(6):534–540.

MiceliJJ et al. The effect of food on the absorption of oral ziprasidone. Psychopharmacol Bull. 2007;40(3):58–68.

Sidana A et al. Ziprasidone and its association with sudden cardiac death - a case report. Indian J Psychiatry.

2004;46(1):79–80.

Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs.

2003;17(6):423–430.

Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am

J Psychiatry. 2001;158(11):1774–1782.

Mandrioli R et al. Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment

of schizophrenia and bipolar disorder. Expert Opin Drug Metab Toxicol. 2015;11(1):149–174.

Boggs D et al. Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving

long-acting injectable antipsychotics. Prim Care Companion CNS Disord. 2013;15(4):4088.

doi:10.4088/PCC.13l01519.

Chen J-X et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized,

double-blind, placebo-controlled, dose–response study. Psychoneuroendocrinology. 2015;58:130–140.

doi:10.1016/j.psyneuen.2015.04.011.

Kelly DL et al. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the

ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic

ELevated prolactin). BMC Psychiatry. 2013;13(1):214. doi:10.1186/1471-244X-13-214.

Cohen J et al. Aripiprazole-induced pathological gambling: a report of 3 cases. Curr Drug Saf. 2011;6(1):51–53.

doi:10.2174/157488611794480016.

Gaboriau L et al. Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports. Addict

Behav. 2014;39(3):562–565. doi:10.1016/j.addbeh.2013.11.005.

Correll CU et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week

randomized,double-blind, placebo-controlled trial. Am J Psychiatry. 2015;(9):870–880.

doi:10.1176/appi.ajp.2015.14101275.

Kane JM et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for

the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1–3):127–135.

doi:10.1016/j.schres.2015.01.038.

Maeda K et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity

modulator. J Pharmacol Exp Ther. 2014:jpet.114.213793 -. doi:10.1124/jpet.114.213793.

REXULTI® (brexpiprazole) tablets (Package Insert). Tokyo, Japan:Osutka Pharmaceutical Co. Ltd; 2015.

Werner FM, Covenas R. New developments in the management of schizophrenia and bipolar disorder: potential

use of cariprazine. Ther Clin Risk Manag. 2015;11:1657–1661. doi:10.2147/TCRM.S64915.

Kane JM et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an

international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367–373.

doi:10.1097/JCP.0000000000000346.

Sachs GS et al. Cariprazine in the treatment of acute mania in bipolar i disorder: a double-blind, placebocontrolled, phase III trial. J Affect Disord. 2015;174:296–302. doi:10.1016/j.jad.2014.11.018.

Durgam S et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of

schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2/3):450–457.

doi:10.1016/j.schres.2013.11.041.

Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly

commercialised second-generation antipsychotic. Int J Clin Pract. 2009;63(8):1237–1248.

Cutler AJ et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S20-S28.

doi:10.1097/JCP.0b013e318169d4ce.

Henry JM, Fuller M. Asenapine: a new antipsychotic option. J Pharm Pract. 2011;24(5):447–451.

doi:10.1177/0897190011422875.

Harvey PD. The clinical utility of lurasidone in schizophrenia : patient considerations. Neuropsychiatr Dis Treat.

2015;11:1103–1109.

Segman RH et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic

schizophrenia. Mol Psychiatry. 2001;6(2):225–229. doi:10.1038/sj.mp.4000842.

Tollefson GD et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and

schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154(4):457–

465. doi:10.1176/ajp.154.4.457.

Kane JM et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with

acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30(2):106–115.

doi:10.1097/JCP.0b013e3181d35d6b.

Moore T et al. The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2006 Update. J

Clin Psychiatry. 2007;68(11):1751–1762. doi:10.4088/JCP.v65n0408.

Buchanan RW et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and

summary statements. Schizophr Bull. 2010;36(1):71–93. doi:10.1093/schbul/sbp116.

NICE. National collaborating centre for mental health, psychosis and schizophrenia in adults: treatment and

management. Clin Guidel 178. 2014. (https://www.nice.org.uk/guidance/cg178).

Gartlehner G et al. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol.

2006;59(10):1040–1048.

Stroup T et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention

Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull.

2003;29(1):15–31.

Stroup TS et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic

schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4):611–

622. doi:10.1176/appi.ajp.163.4.611.

McEvoy JP et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with

chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry.

2006;163(4):600–610. doi:10.1176/appi.ajp.163.4.600.

Stroup TS et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res. 2009;107(1):1–12.

doi:10.1016/j.schres.2008.10.011.

Lewis S, Lieberman J. CATIE and CUtLASS: can we handle the truth? Br J Psychiatry. 2008;192(3):161–163.

doi:10.1192/bjp.bp.107.037218.

Lewis SW et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new

atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug

treatment. Health Technol Assess (Rockv). 2006;10(17):iii–iv, ix–xi, 1–165. doi:10.3310/hta10170.

Boter H et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on

response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009;115(2/3):97–103.

doi:10.1016/j.schres.2009.09.019.

Leucht S et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.

Lancet. 2009;373(9657):31–41. doi:10.1016/S0140-6736(08)61764-X.

Zink M et al. Polypharmacy in schizophrenia. Nervenarzt. 2011;82(7):853–858.

doi:10.1097/YCO.0b013e3283366427.

Kogut SJ et al. Prescribing of antipsychotic medication in a Medicaid population: use of polytherapy and off label

dosages. J Manag Care Pharm. 2005;11(1):17–24.

Centorrino F et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control

study of risks versus benefits. Am J Psychiatry. 2004;161(4):700–706. doi:10.1176/appi.ajp.161.4.700.

Barnes TRE, Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs.

2011;25(5):383–399. doi:10.2165/11587810-00085-00000.

Goren JL et al. Development and delivery of a quality improvement program to reduce antipsychotic

polytherapy. J Manag Care Pharm. 2010;16(6):393–401.

Preskorn SH, Lacey RL. Polypharmacy: when is it rational? J Psychiatr Pract. 2007;13(2):97–105.

doi:10.1097/01.pra.0000265766.25495.3b.

.

.

.

.

.

.

.

153.

154.

.

.

.

158.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

Dufresne RL, Wagner RL. Antipsychotic-withdrawal akathisia versus antipsychotic-induced akathisia: further

evidence for the existence of tardive akathisia. J Clin Psychiatry. 1988;49(11):435–438.

Barnes TR, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry. 1985;42(9):874–878.

doi:10.1097/00004714-198602000-00012.

Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672–676.

doi:10.1192/bjp.154.5.672.

Citrome L et al. Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other

d i s o r d e r s . Am J Manag Care. 2007;(December):1–12.

http://www.ajmc.com/journals/supplement/2007/2007-12-vol12-n1-decisionmakernews/dec07-

2760p1-12. Accessed July 3, 2017.

Margolese HC et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology

and mechanisms of induction. Can J Psychiatry. 2005;50(9):541–547.

Correll CU et al. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a

systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–425. doi:10.1176/appi.ajp.161.3.414.

Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry. 2000;61(S4):27–32.

Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov

Disord. 2006;21(5):589–598. doi:10.1002/mds.20823.

Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000;61(S4):5–9.

Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin

Psychiatry. 2000;61(S4):15–20.

Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry.

2007;20(2):131–137. doi:10.1097/YCO.0b013e328017f6b1.

Bergman J et al. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement

disorders. J Clin Psychiatry. 2005;66(1):107–110. doi:10.4088/JCP.v66n0115.

Weber SS et al. Diazepam in tardive dyskinesia. Drug Intell Clin Pharm. 1983;17(7/8):523–527.

Bhidayasiri R et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline

Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463–469.

doi:10.1212/WNL.0b013e31829d86b6.

Tenback DE et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients

from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. J Clin Psychiatry.

2005;66(9):1130–1133. doi:10.1016/S0084-3970(08)70526-7.

Hideaki T et al. Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey. BMC Oral

Health. 2012;12(32).

Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophr Bull. 2012;38(3):592–598.

doi:10.1093/schbul/sbq137.

Desmarais JE et al. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J

Psychopharmacol. 2012;26(9):1167–1174. doi:10.1177/0269881112447988.

Leung JYT et al. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system.

Pharmacol Ther. 2012;135(2):113–122. doi:10.1016/j.pharmthera.2012.04.003.

Iqbal MM et al. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry.

2003;15(1):33–48.

Miller DD. Review and management of clozapine side effects. J Clin Psychiatry. 2000;61(Suppl 8):14–19.

Beach SR et al. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics.

2013;54(1):1–13. doi:10.1016/j.psym.2012.11.001.

FDA Psychopharmacological Drugs Advisory Committee. 19 July 2000 Briefing Document for Zeldox Capsules

(Ziprasidone HCl). 2000.

Harrigan EP et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence

and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24(1):62–69.

doi:10.1097/01.jcp.0000104913.75206.62.

Potkin SG et al. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6

and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol. 2013;33(1):3–10.

Bostwick JR et al. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009;29(1):64–73.

doi:10.1097/JCP.0b013e31818ba5d8.

Leucht S et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multipletreatments meta-analysis. Lancet. 2013;382(9896):951–962. doi:10.1016/S0140-6736(13)60733-3.

.

.

.

.

177.

.

.

.

.

.

.

.

.

.

.

.

.

190.

.

.

.

194.

.

.

.

Kreyenbuhl J et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment

recommendations 2009. Schizophr Bull. 2010;36(1):94–103. doi:10.1093/schbul/sbp130.

Melmed S et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.

J Clin Endocrinol Metab. 2011;96(2):273–288. doi:10.1210/jc.2010-1692.

Lehman AF et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment

recommendations 2003. Schizophr Bull. 2004;30(2):193–217.

Yasui-Furukori N et al. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia

induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol. 2010;30(5):596–599.

doi:10.1097/JCP.0b013e3181ee832d.

Kane JM et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive

aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone

monotherapy. J Clin Psychiatry. 2009;70(10):1348–1357. doi:10.4088/JCP.09m05154yel.

Shim JC et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced

hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164(9):1404–1410.

doi:10.1176/appi.ajp.2007.06071075.

Kinon BJ et al. Association between early and rapid weight gain and change in weight over one year of

olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol.

2005;25(3):255–258. doi:10.1097/01.jcp.0000161501.65890.22.

Jaton LA et al. Differential rate of weight gain present among patients treated with olanzapine. Schizophr Res.

2003;60:357S.

Sernyak MJ et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of

schizophrenia. Am J Psychiatry. 2002;159(4):561–566. doi:10.1176/appi.ajp.159.4.561.

Newcomer JW et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch

Gen Psychiatry. 2002;59(4):337–345.

Ryan MCM, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome.

Life Sci. 2002;71(3):239–257. doi:10.1016/S0024-3205(02)01646-6.

Kroeze WK et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical

antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519–526.

Poyurovsky M et al. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapineinduced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol. 2005;20(2):101–103.

Ellingrod VL et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and

olanzapine. Am J Med Genet B Neuropsychiatr Genet. 2005;134B(1):76–78.

Reynolds GP et al. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene

polymorphism. Lancet. 2002;359(9323):2086–2087.

Silvestre JS, Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict

the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol. 2005;27(5):289–304.

Atmaca M et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin

Psychiatry. 2003;64(5):598–604. doi:10.4088/JCP.v64n0516.

Hägg S et al. Leptin concentrations are increased in subjects treated with clozapine or conventional

antipsychotics. J Clin Psychiatry. 2001;62(11):843–848. doi:10.4088/JCP.v62n1102.

Ellingrod VL et al. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from

olanzapine treatment in persons with schizophrenia. Psychopharmacol Bull. 2007;40(1):57–62.

Laimer M et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry.

2006;67(3):421–424. doi:10.4088/JCP.v67n0313.

American Diabetes Association et al. Consensus development conference on antipsychotic drugs and obesity

and diabetes. Diabetes Care. 2004;27(2):267–272.

Henderson DC et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic

study. Am J Psychiatry. 2000;157(6):975–981. doi:10.1176/appi.ajp.157.6.975.

Dufresne RL. Weighing in: emergent diabetes mellitus and second-generation antipsychotics. Ann

Pharmacother. 2007;41(10):1725–1727. doi:10.1345/aph.1K362.

Melkersson KI et al. Different influences of classical antipsychotics and clozapine on glucose-insulin

homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry. 1999;60(11):783–791.

Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes,

hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry. 2001;58(12):1172–1176.

doi:10.1001/archpsyc.58.12.1172.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

Marder SR et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull.

2002;28(1):5–16.

Ghaeli P, Dufresne RL. Elevated serum triglycerides with clozapine resolved with risperidone in four patients.

Pharmacotherapy. 1999;19(9):1099–1101. doi:10.1592/phco.19.13.1099.31586.

Kingsbury SJ et al. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry.

2001;62(5):347–349.

Cohen S et al. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with

mental retardation. J Clin Psychiatry. 2003;64(1):60–62.

Newcomer JW et al. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density

lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophr Res.

2008;106(2/3):300–307.

McGrath JJ. Myths and plain truths about schizophrenia epidemiology - The NAPE lecture 2004. Acta Psychiatr

Scand. 2005;111(1):4–11. doi:10.1111/j.1600-0447.2004.00467.x.

Goethe JW et al. Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving

antipsychotics: a retrospective chart review. J Clin Psychiatry. 2007;68(1):22–28.

Enez Darcin A et al. Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their

siblings. Schizophr Res. 2015. doi:10.1016/j.schres.2015.05.004.

Weissman EM et al. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics.

J Clin Psychiatry. 2006;67(9):1323–1326. doi:10.4088/JCP.v67n0901.

Saari KKM, Lindeman SMS, Viilo KM, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia:

the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry. 2005;66(5):559–563.

Ringen PA et al. Increased mortality in schizophrenia due to cardiovascular disease: a non-systematic review of

epidemiology, possible causes, and interventions. Front Psychiatry. 2014;5(September):1–11.

doi:10.3389/fpsyt.2014.00137.

Beckman MG et al. Venous thromboembolism. A public health concern. Am J Prev Med. 2010;38(4,

Suppl):S495-S501. doi:10.1016/j.amepre.2009.12.017.

Masopust J et al. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry Clin

Neurosci. 2012;66(7):541–552. doi:10.1111/pcn.12001.

Zhang R et al. Antipsychotics and venous thromboembolism risk: a meta-analysis (Provisional abstract).

Pharmacopsychiatry. 2011;44(5):183–188.

Paciullo CA. Evaluating the association between clozapine and venous thromboembolism. Am J Heal Pharm.

2008;65(19):1825–1829. doi:10.2146/ajhp070638.

Brunet N et al. Venous thromboembolism in patients prescribed aripiprazole: a case series. In: Presented at the

49th ASHP Midyear Clinical Meeting and Exhibition on December 7–11, 2014 in Anaheim, California.

Srihari VH, Lee TW. Pulmonary embolism in a patient taking clozapine. BMJ. 2008;336(7659):1499–1501.

doi:10.1136/bmj.39545.690613.47.

Allenet B et al. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf.

2011;21(1):42–48.

Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly

patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2014;165(22):2677–

2682. doi:10.1001/archinte.165.22.2677.

Layton D et al. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in

observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in

England including patients with dementia. J Psychopharmacol. 2005;19(5):473–482.

Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. Cmaj.

2002;167(11):1269–1270.

Huybrechts KF et al. Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr

Soc. 2012;60(3):420–429. doi:10.1055/s-0029-1237430.Imprinting.

Schneider LS et al. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of

randomized placebo-controlled trials. JAMA. 2005;294(15):1934–1943.

Tse L et al. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr

Neuropharmacol. 2015;13(3):395–406.

Hoffmann MS et al. Heat stroke during long-term clozapine treatment: should we be concerned about hot

weather? Trends Psychiatry Psychother. 2016;38(1):56–59. doi:10.1590/2237-6089-2015-0066.

Elvevåg B et al. Habitual prospective memory in schizophrenia. BMC Psychiatry. 2003;7:1–7. doi:10.1186/1471-

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

247.

.

.

.

.

244X-3-9.

Davis JM. Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry. 1985;11(2):18–21.

Sendt K-V et al. A systematic review of factors influencing adherence to antipsychotic medication in

schizophrenia-spectrum disorders. Psychiatry Res. 2015;225(1/2):14–30. doi:10.1016/j.psychres.2014.11.002.

Lacro JP et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a

comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892–909.

Czobor P et al. Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and

EUFEST studies. Eur Neuropsychopharmacol. 2015:1–9. doi:10.1016/j.euroneuro.2015.04.003.

Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry. 2001;50(11):898–

911. doi:10.1016/s0006-3223(01)01271-9.

Rosenheck RA. Outcomes, costs, and policy caution: a commentary on the cost utility of the latest antipsychotic

drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1074–1087.

Agid O et al. Clozapine’s role in the treatment of first-episode schizophrenia. Treat Psychiatry.

2013;170(February):146–151.

Manu P et al. When can patients with potentially life-threatening adverse effects be rechallenged with

clozapine? A systematic review of the published literature. Schizophr Res. 2012;134(2/3):180–186.

Devinsky O et al. Clozapine-related seizures. Neurology. 1991;41(3):369–371.

Varma S. Clozapine-related EEG changes andseizures: dose and plasma-level relationships. Ther Adv

Psychopharmacol. 2011;1(2):66. doi:10.1177/.

Lundblad W et al. Medical management of patients on clozapine: a guide for internists. J Hosp Med.

2015;10(8):537–543. doi:10.1002/jhm.2345.

Ronaldson KJ, Fitzgerald PB, McNeil JJ. Clozapine-induced myocarditis, a widely overlooked adverse reaction.

Acta Psychiatr Scand. 2015;132(4):231–240. doi:10.1111/acps.12416.

Kane JM et al. The field of schizophrenia: strengths, weaknesses, opportunities, and threats. Schizophr Bull.

2012;38(1):1–4. doi:10.1093/schbul/sbr131.

Ronaldson KJ et al. Observations from 8 cases of clozapine rechallenge after development of myocarditis. J Clin

Psychiatry. 2012;73(2):252–254. doi:10.4088/JCP.11l07467.

Bird AM et al. Current treatment strategies for clozapine-induced sialorrhea. Ann Pharmacother.

2011;45(5):667–675. doi:10.1345/aph.1P761.

Hiemke C et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.

Pharmacopsychiatry. 2011;44(6):195–235.

Perry PJ et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory

schizophrenic patients. Am J Psychiatry. 1991;148(2):231–235. doi:10.1176/ajp.148.2.231.

Premkumar TS, Pick J. Lamotrigine for schizophrenia (Review). Cochrane Database Syst Rev. 2008;

(4):CD005962.

Leucht S et al. Lithium for schizophrenia. Cochrane Database Syst Rev. 2015;10(10):CD003834.

doi:10.1002/14651858.CD003834.pub3.

Tseng PT et al. Significant effect of valproate augmentation therapy in patients with schizophrenia: a metaanalysis study. Med. 2016;95(4):e2475. doi:10.1097/MD.0000000000002475.

Leucht S et al. Carbamazepine for schizophrenia. Cochrane Database Syst Rev. 2014;5:CD001258.

doi:10.1002/14651858.CD001258.pub3.

An Der Heiden W et al. Depression in the long-term course of schizophrenia. Eur Arch Psychiatry Clin

Neurosci. 2005;255(3):174–184. doi:10.1007/s00406-005-0585-7.

Caldwell CB, Gottesman II. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr

Bull. 1990;16(4):571–589. doi:10.1093/schbul/16.4.571.

Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol.

2010;24(4, Suppl):81–90. doi:10.1177/1359786810385490.

Pompili M et al. Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry.

2007;6:10. doi:10.1186/1744-859X-6-10.

Kasper S. Treatment of depressive symptoms with quetiapine. Expert Rev Neurother. 2003;3(4):417–423.

doi:10.1586/14737175.3.4.417.

Tollefson GD, Sanger TM. Depressive Signs and Symptoms in Schizop Lu, Yili Thieme, Martha E.hrenia. Arch

Gen Psychiatry. 1998;55(3):250. doi:10.1001/archpsyc.55.3.250.

Siris SG. Depression in schizophrenia: perspective in the era of “atypical” antipsychotic agents. Am J

Psychiatry. 2000;157(9):1379–1389. doi:10.1176/appi.ajp.157.9.1379.

.

.

.

.

.

.

.

.

.

.

.

263.

264.

.

.

.

.

.

.

.

.

.

.

.

.

Terevnikov V et al. Randomized Controlled Trials of Add-On Antidepressants in Schizophrenia. Int J

Neuropsychopharmacol. 2015;18(9):1–14. doi:10.1093/ijnp/pyv049.

Rummel C et al. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and

pronounced negative symptoms: a systematic review of randomized trials. Schizophr Res. 2005;80(1):85–97.

doi:10.1016/j.schres.2005.07.035.

Plasky P. Antidepressant usage in schizophrenia. Schizophr Bull. 1991;17(4):649–657.

Lehman AF et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J

Psychiatry. 2004;161(2, Suppl):1–56. doi:10.1176/appi.books.9780890423363.45859.

Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pr. 2009;15:183.

American College of Obstetricians and Gynecologists. Use of psychiatric medications during pregnancy and

lactation. Obs Gynecol. 2008;117(6):1472–1483.

Cohen LS et al. Reproductive safety of second-generation antipsychotics: current data from the Massachusetts

General Hospital national pregnancy registry for atypical antipsychotics. Am J Psychiatry. 2016;173(3):263–

270. doi:10.1176/appi.ajp.2015.15040506.

US Food and Drug Administration FDA Drug Safety Communication. Antipsychotic drug labels updated on use

during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. 2016.

http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm. Accessed March 1, 2016.

Correll CU et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline

results from the RAISE-ETP study. JAMA Psychiatry. 2014;71(12):1350–1363.

doi:10.1001/jamapsychiatry.2014.1314.

McGorry PD et al. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J

Clin Psychiatry. 2009;70(9):1206–1212. doi:10.4088/JCP.08r04472.

Alvarez-Jimenez M et al. Preventing the second episode: a systematic review and meta-analysis of psychosocial

and pharmacological trials in first-episode psychosis. Schizophr Bull. 2011;37(3):619–630.

doi:10.1093/schbul/sbp129.

McEvoy JP et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early

psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050–1060.

doi:10.1176/ajp.2007.164.7.1050.

Schooler N et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J

Psychiatry. 2005;162(5):947–953. doi:10.1176/appi.ajp.162.5.947.

Sanger TM et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry.

1999;156(1):79–87. doi:10.1176/ajp.156.1.79.

Cannon TD et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North

America. Arch Gen Psychiatry. 2008;65(1):28–37. doi:10.1001/archgenpsychiatry.2007.3.

Amminger GP. Long-chain omega3 fatty acids for indicated prevention of psychotic disorders: a randomized,

placebo-controlled trial. JAMA. 2010;67(2):146–154.

Amminger GP, McGorry PD. Update on omega-3 polyunsaturated fatty acids in early-stage psychotic disorders.

Neuropsychopharmacology. 2012;37(1):309–310. doi:10.1038/npp.2011.187.

Kane JM et al. Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes

From the NIMH RAISE Early Treatment Program. Am J Psychiatry. 2016;173(4):362–372.

doi:10.1176/appi.ajp.2015.15050632.

Birchwood M et al. The UK national evaluation of the development and impact of Early Intervention Services

(the National EDEN studies): study rationale, design and baseline characteristics. Early Interv Psychiatry.

2014;8(1):59–67. doi:10.1111/eip.12007.

Marshall M et al. Impact of early intervention services on duration of untreated psychosis: data from the

National EDEN prospective cohort study. Schizophr Res. 2014;159(1):1–6. doi:10.1016/j.schres.2014.07.005.

Marshall M et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode

patients: a systematic review. Arch Gen Psychiatry. 2005;62(9):975–983.

Keefe RSE et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in

the CATIE Trial. Arch Gen Psychiatry. 2007;64(6):633–647. doi:10.1001/archpsyc.64.6.633.

Eack SM et al. Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year

randomized controlled trial. Psychiatr Serv. 2009;60(11):1468–1476. doi:10.1176/appi.ps.60.11.1468.

Eack SM et al. One-year durability of the effects of cognitive enhancement therapy on functional outcome in

early schizophrenia. Schizophr Res. 2010;120(1–3):210–216. doi:10.1016/j.schres.2010.03.042.

Robinson D et al. Predictors of relapse following response from a first episode of schizophrenia or

.

.

.

280.

281.

282.

283.

284.

285.

286.

.

.

289.

290.

291.

292.

293.

294.

295.

.

297.

298.

299.

300.

301.

302.

.

.

305.

306.

307.

308.

309.

schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–247.

Wunderink L et al. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis:

relapse rates and functional outcome. J Clin Psychiatry. 2007;68(5):654–661.

Wunderink L et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose

reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical

trial. JAMA Psychiatry. 2013;70(9):913–920. doi:10.1001/jamapsychiatry.2013.19.

Thioridazine hydrochloride [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; August 2014.

Trifluoperazine hydrochloride [package insert]. Morgantown, WV: Mylan Pharmaceuticals, Inc.; March 2015.

Moban (Molindone Hydrochloride Tablets, USP [package insert]. Chadds Ford, Pennsylvania: Endo

Pharmaceuticals; June, 2009.

Chlorpromazine hydrochloride [package insert]. Eatontown, NJ: West-ward Pharmaceutical Corp.; June 2012.

Fluphenazine hydrochloride [package insert]. Philadelphia, PA: Lannett Company, Inc.; November 2011.

Haldol (haloperidol) [package insert]. Titusville, NJ:Janssen Pharmaceuticals; January 2016.

Loxapine succinate [package insert]. New Castle, DE: Marlex Pharmaceuticals, Inc.; February 2016.

Perphenazine [package insert]. Princeton, NJ: Sandoz, Inc.; December 2015.

Navane (thiothixene) [package insert]. New York, NY: Pfizer, Inc.; January 2011.

Zyprexa (olanzapine) [package insert]. Indianapolis, IN:Eli Lilly and Company;2010.

Vraylar (cariprazine tablets) [package insert]. Parsippany, NJ: Actavis Pharma, Inc.; September 2015.

Latuda (lurasidone HCl tablets) [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; July 2013.

Rexulti (brexpiprazole tablets) [package insert]. Tokyo, Japan: Otsuka Pharmaceutical Company; August 2015.

Saphris (asenapine tablets) [package insert]. Whitehouse Station Inc.; March 2013., NJ: Merck & Company.

Clozaril (clozapine tablets) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;

September 2015.

Invega (paliperidone extended-release tablets) [package insert]. Titusville, NJ: Janssen Pharmaceutical; June

2011.

Fanapt (iloperidone tablets) [package insert]. Washington, DC: Vanda Pharmaceuticals Inc.; January 2016.

Abilify (aripiprazole) [package insert].Wallingford, CT: Bristol-Myers Squibb; 2011.

Garza-Trevino ES, Hollister LE, Overall JE, Alexander WF. Efficacy of combinations of intramuscular

antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry. 1989;146(12):1598–

1601. doi:10.1176/ajp.146.12.1598.

Lesem J. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic

patients. J Clin Psychiatry. 2001;62(1):12–18.

Brook S et al. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute

psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry. 2000;61(12):933–941.

Currier GW et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with

risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry.

2004;65(3):386–394.

Altamura AC et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs.

2003;63(5):493–512.

Andrezina R et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia

or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.

Psychopharmacol. 2006;188(3):281–292. doi:10.1007/s00213-006-0541-x.

Breier A et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and

haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59(5):441–448.

Aristada (aripiprazole lauroxil extended-release injectable suspension) [package insert]. Waltham, MA:

Alkermes, Inc.; October 2015.

Risperdal Consta (risperidone long-acting injection) [package insert]. Titusville, NJ: Janssen Pharmaceutical;

March 2016.

Invega Trinza (paliperidone palmitate extended-release injectable suspension) [package insert]. Titusville, NJ:

Janssen Pharmaceutical; May 2015.

Zyprexa Relprevv (olanzapine extended release injectable suspension) [package insert]. Indianapolis, IN: Eli Lilly

and Company; September 2015.

Invega Sustenna (paliperidone palmitate extended-release injectable suspension) [package insert]. Titusville, NJ:

Janssen Pharmaceutical; June 2015.

Fluphenazine Decanoate (fluphenazine decanoate extended-release injection) [package insert]. Weston, FL:

310.

.

Apotex Corp.; June 2001.

Abilify Maintena (aripiprazole for extended-release injectable suspension) [package insert]. Tokyo, Japan:

Otsuka Pharmaceutical Company; July 2015.

Haldol Decanoate (haloperidol decanoate extended-release injection) [package insert]. Titusville, NJ: Janssen

Pharmaceutical; January 2016.

p. 1812

Depression is a common and often chronic disorder that may manifest at

any time in one’s life. Diagnostic criteria for major depression include a

minimum of five symptoms persisting for at least 2 weeks. One of these

symptoms must be either depressed mood or anhedonia. Suicidal

ideation should be assessed in all patients.

Case 86-1 (Question 1),

Table 86-4

A variety of treatment modalities are available for the management of

depression. These include prescription medications, psychotherapy, and

somatic treatments. Prescription medications and/or psychotherapy are

indicated for depressive symptoms that are moderate to severe in

nature, whereas somatic treatments are for severe refractory cases.

Case 86-1 (Question 2),

Case 86-2 (Questions 1, 2),

Case 86-3 (Question 2)

All of the prescription medications that are currently available are

equally effective and possess the same delayed onset of therapeutic

effects. Selection of an antidepressant is based on many factors,

including previous response to medication, age, reproduction status, and

both medical and psychiatric comorbidities.

Case 86-1 (Questions 2, 4),

Case 86-2 (Question 2)

Case 86-4 (Question 1),

Table 86-6

SSRIs are regarded as the initial treatment of choice for most depressed

patients. They are inexpensive and effective for comorbid anxiety

conditions, and possess a lower side effect burden than other

antidepressants overall. Side effects are generally mild and transient.

Case 86-1 (Question 2),

Case 86-2 (Question 1)

Educating the patient regarding side effects, how to monitor for efficacy,

and the duration of treatment is important action for successful

treatment.

Case 86-1 (Question 3),

Case 86-3 (Question 3),

Table 86-10

The goal of antidepressant treatment is remission of symptoms. Once

remission is achieved, the general recommendation is to continue the

effective antidepressant regimen for a minimum of 6 months.

Case 86-1 (Question 3),

Table 86-10

Because only half of depressed patients will achieve remission with the

first antidepressant selected, clinicians should have a comprehensive

understanding of the role many antidepressants may have in optimizing

outcomes. Clinicians should be familiar with switching antidepressants in

patients with an incomplete response, and the merits of augmentation

strategies.

Case 86-2 (Questions 1–3)

Untreated depression in children under 18 has a significant risk of Case 86-3 (Questions 1, 2)

suicide. Treatment consists of talking therapy and specific

antidepressants, which is different than the broad options available to

adults.

Depression and chronic pain are commonly comorbid, and

pharmacologic treatment that addresses both is recommended. This

makes the SNRI class of antidepressants preferred.

Case 86-4 (Question 1)

p. 1813

p. 1814

INTRODUCTION

In general, depressive disorders are enormous health concerns that are often

misdiagnosed or undertreated. The physical and social dysfunction associated with

depression is profound and is believed to outweigh many other chronic medical

conditions, including hypertension, diabetes, and arthritis.

1 The Medical Outcomes

Study determined that the degree of impairment in depressed individuals is

comparable to that seen in patients with chronic heart disease.

2 The financial

ramifications of depression are tremendous and place an overwhelming burden on

our society. In 2000, the estimated cost of depression in the United States was $83.1

billion annually, with most of these costs ($51.5 billion) attributed to lost

productivity and absenteeism in the workplace.

1,3

Epidemiology

Since World War II, the lifetime incidence of depression has been rising steadily in

studied populations. The annual incidence of all mood disorders is approximately

10% in the adult population, and 1 in 15 adults (6.7%) will suffer from an episode of

major depression during any 12-month period.

4 Various studies from Europe and the

United States have estimated the 1 year and lifetime prevalence to be 4.1% and

6.7%, respectively.

5 Although the incidence of depression is remarkably similar

across various races and ethnic groups, the illness may be slightly more common in

lower socioeconomic classes and women having double the incidence than men.

1,5

The onset of depression occurs most commonly in the late 20s, but there is a wide

range, and the first episode may actually present at any age. Genetic factors appear to

play a major role in the cause of depression. The offspring of depressed individuals

are 2.7 times more likely to have depression if one parent is afflicted, and 3.0 times

more likely if both parents suffer from depression.

6 Concordance rates for

monozygotic (identical) twins range from 54% to 65%, whereas the corresponding

rates in dizygotic (fraternal) twins range from 14% to 24%.

7 Genetic factors may also

1.

2.

3.

4.

5.

6.

7.

8.

predispose individuals to an earlier onset of depression (younger than 30 years of

age).

8 Additionally, there is clear evidence that depression may occur as a result of

stressful events (i.e., environmental factors) in one’s life. These factors include a

difficult childhood, physical or verbal abuse, pervasive low self-esteem, death of a

loved one, loss of a job, and the end of a serious relationship. Acute depressive

episodes are often attributed to a combination of environmental and genetic factors.

For instance, individuals carrying a genetic predisposition to mood disorders may

undergo a stressful experience that ultimately triggers the manifestation of depressive

symptomatology. Depression may also occur spontaneously among people who

appear to lack any obvious genetic or environmental predisposition.

Diagnosis and Classification

When assessing a person for depression, it is important to recognize the level of

impairment due to the symptoms. Just as with all biologic systems, the body can

function well within a particular range (e.g., serum potassium or BP). Mood is not

different; as long as the depressive symptoms are not prolonged or impairing, there

would be no reason to aggressively treat. Once the depression is severe enough to

impact functioning or induce harm, it requires treatment.

Major depressive disorder (MDD) may manifest as a single episode, but it is more

commonly a series of recurrent events. Thus, in most patients, depression is a chronic

illness.

5 The frequency of recurrent episodes is highly variable, with some people

experiencing discrete episodes separated by many years of relatively normal mood

(euthymia), and others experiencing residual symptoms between episodes that may

never completely remit. The risk of future episodes appears to increase

disproportionately with the chronicity of the illness. For instance, after the first

episode there is a 50% likelihood of a second episode. After the second, there is a

70% chance of a third, and with the third episode comes nearly a 90% incidence of a

fourth.

Table 86-1